Literature DB >> 16406982

Evidence for a biopsy derived grade artifact among larger prostate glands.

Girish S Kulkarni1, Rami Al-Azab, Gina Lockwood, Ants Toi, Andrew Evans, John Trachtenberg, Michael A S Jewett, Antonio Finelli, Neil E Fleshner.   

Abstract

PURPOSE: The PCPT has demonstrated a higher incidence of high grade (Gleason pattern 4 or greater) prostate cancers among men randomized to finasteride. One plausible explanation for this finding is that tumor grade as assigned by TRUS guided biopsy is artifactually associated with prostate volume.
MATERIALS AND METHODS: We evaluated our institutional data set of TRUS guided biopsies in the last 3 years and identified 369 cases of prostate cancer that fit the criteria of PSA less than 10 ng/ml, biopsy at our center and RP at our center. We identified risk factors for Gleason pattern 4 or greater on biopsy and then on RP specimens from the same patients using univariate and multiple logistic regression analyses. Assessed covariates included patient age, PSA and TRUS volume.
RESULTS: Risk factors for Gleason pattern 4 or greater in the biopsy specimens included age (p = 0.01), hypoechoic lesions on TRUS (p <0.001) and TRUS volume (p = 0.008). However, among RP specimens TRUS volume (p = 0.60) became nonsignificant of Gleason pattern 4 or greater on multivariable analysis. Although prostate volume was a predictor for biopsy derived high grade disease it was not predictive of true histological grade.
CONCLUSIONS: These data suggest that simply having a larger prostate results in fewer high grade cancers diagnosed at biopsy. Prostatectomy results in the same men suggest sampling artifact, as the distribution of cancer grade is not associated with prostate volume. These findings provide evidence that the increase in higher grade tumors among men in the finasteride arm of PCPT may simply result from prostate volume reduction.

Entities:  

Mesh:

Year:  2006        PMID: 16406982     DOI: 10.1016/S0022-5347(05)00236-3

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  27 in total

1.  Epidemiology of prostate cancer and treatment remarks.

Authors:  Stefano Arcangeli; Valentina Pinzi; Giorgio Arcangeli
Journal:  World J Radiol       Date:  2012-06-28

2.  Association Between Computed Tomographic Features and Kirsten Rat Sarcoma Viral Oncogene Mutations in Patients With Stage I Lung Adenocarcinoma and Their Prognostic Value.

Authors:  Hua Wang; Matthew B Schabath; Ying Liu; Olya Stringfield; Yoganand Balagurunathan; John J Heine; Steven A Eschrich; Zhaoxiang Ye; Robert J Gillies
Journal:  Clin Lung Cancer       Date:  2015-11-12       Impact factor: 4.785

Review 3.  Is it time to consider a role for MRI before prostate biopsy?

Authors:  Hashim U Ahmed; Alex Kirkham; Manit Arya; Rowland Illing; Alex Freeman; Clare Allen; Mark Emberton
Journal:  Nat Rev Clin Oncol       Date:  2009-04       Impact factor: 66.675

4. 

Authors:  Neil Fleshner
Journal:  Can Urol Assoc J       Date:  2009-06       Impact factor: 1.862

5.  Temporal changes in the pathologic assessment of prostate cancer.

Authors:  M Scott Lucia; Adrie van Bokhoven
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

6.  5-alpha reductase inhibitors in patients on active surveillance: do the benefits outweigh the risk?

Authors:  Ghazi Al Edwan; Neil Fleshner
Journal:  Curr Urol Rep       Date:  2013-06       Impact factor: 3.092

7.  Predicting the risk of harboring high-grade disease for patients diagnosed with prostate cancer scored as Gleason ≤ 6 on biopsy cores.

Authors:  Thomas Seisen; Françoise Roudot-Thoraval; Pierre Olivier Bosset; Aurélien Beaugerie; Yves Allory; Dimitri Vordos; Claude-Clément Abbou; Alexandre De La Taille; Laurent Salomon
Journal:  World J Urol       Date:  2014-07-02       Impact factor: 4.226

8.  [The Prostate Cancer Prevention Trial (PCPT). Relevance for clinical practice].

Authors:  B J Schmitz-Dräger; C Fischer; E Bismarck; H J Dörsam; G Lümmen
Journal:  Urologe A       Date:  2007-10       Impact factor: 0.639

9.  Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume.

Authors:  Jay H Fowke; Saundra S Motley; Joseph A Smith; Michael S Cookson; Raoul Concepcion; Sam S Chang; Susan Byerly
Journal:  J Urol       Date:  2009-03-14       Impact factor: 7.450

10.  The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator.

Authors:  Donna P Ankerst; Cathee Till; Andreas Boeck; Phyllis Goodman; Catherine M Tangen; Ziding Feng; Alan W Partin; Daniel W Chan; Lori Sokoll; Jacob Kagan; John T Wei; Ian M Thompson
Journal:  J Urol       Date:  2013-01-09       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.